Investigating how empagliflozin affects heart function in adults at risk for heart failure
Official title: Effects of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
Funded at University of Minnesota · NIH-11067755 · Data updated 2026-11-12
This study is looking at how the medication empagliflozin might help improve heart function in adults who are at risk for heart failure but don’t have it yet, and we’re inviting people from the University of Minnesota's Cardiology clinic to join us for this 9-month trial.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | April 5, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $201,744 |
| NIH project number | 5K23HL168153-02 |
| Project ID | NIH-11067755 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 21 years old who are at risk for heart failure but do not have a current diagnosis of heart failure or diabetes.
✕Less likely to help
Patients who already have a diagnosis of heart failure or diabetes may not benefit from this research.
What this research studies
This research explores the effects of empagliflozin, a medication that inhibits sodium-glucose cotransporters, on the function of the left atrium in adults who are at risk for heart failure but do not have a diagnosis of heart failure or diabetes. The study will involve a 9-month double-blind, placebo-controlled trial with 80 participants, utilizing advanced echocardiography techniques to assess changes in heart function. By examining the relationship between empagliflozin and left atrial function, the research aims to uncover potential therapeutic benefits for preventing heart failure. Participants will be recruited from the Cardiology clinic at the University of Minnesota.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for preventing heart failure in at-risk individuals.
How similar studies have gone: Previous research has shown that SGLT2 inhibitors can reduce cardiovascular events, indicating potential for success in similar approaches.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Van't Hof, Jeremy R. — University of Minnesota
- Study coordinator: Van't Hof, Jeremy R.
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.